Novel HCV vaccine antigens and nanoparticles
新型 HCV 疫苗抗原和纳米颗粒
基本信息
- 批准号:10557879
- 负责人:
- 金额:$ 56.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2027-01-31
- 项目状态:未结题
- 来源:
- 关键词:Animal ModelAntibodiesAntibody ResponseAntibody-mediated protectionAntigen PresentationAntigensAntiviral AgentsArtificial nanoparticlesB cell repertoireB-LymphocytesBindingBiological AssayCell SeparationCirrhosisClinical TrialsComplexComputer ModelsDataDeveloping CountriesDevelopmentEngineeringEpitopesFaceGeneticGenotypeGlycoproteinsGoalsHepatitis C VaccineHepatitis C virusHeterodimerizationHumanImmune systemImmunizationImmunizeImmunodominant EpitopesIn VitroInfectionKnowledgeMacaca mulattaModelingModificationMolecular ConformationMusMutagenesisOutcomePolysaccharidesPopulationPredispositionPrimary carcinoma of the liver cellsProductionPropertyProteinsPublic HealthReactionRecombinantsScaffolding ProteinScanningSiteStructureSurfaceTransmembrane DomainVaccinationVaccine AntigenVaccine DesignVaccinesViralViral AntigensViral Envelope ProteinsVirusclinical developmentcombatcost effectivedesignflexibilityimmunogenicityimprovedin vivoin vivo evaluationmarginalizationmouse modelnanoparticleneutralizing antibodynext generation sequencingnonhuman primatenovelpandemic viruspreferenceprotein foldingrational designresponseself assemblysocial groupvaccine candidatevaccine developmentvaccine immunogenicityvaccine-induced antibodiesvirus envelope
项目摘要
Project Summary
Hepatitis C virus (HCV) infects 1-2% of the world population and poses a significant threat to public health.
Recent studies have identified a panel of broadly neutralizing antibodies (bnAbs) and their genetic preferences.
The crystal structures of various HCV E2 constructs in complex with bnAbs and non-nAbs provide a structural
basis for rational vaccine design. In Project 2 of this P01 proposal, we will combine structural optimization of
HCV antigens, nanoparticle engineering, in vivo assessment, and next-generation sequencing (NGS) of B-cell
repertoires to assist in rational design of HCV vaccines that can elicit a bnAb response. The Specific Aims in
this project are: (1) To develop vaccine antigens to target multidonor class antibody responses. The
major virus neutralizing site, the E2 neutralizing face (E2 NF), is a well-known multidonor class antibody target
on HCV. E2 NF is conformationally flexible and is surrounded and protected by immunodominant variable
loops and N-glycans. The antigenic surface at and around E2 NF will be optimized by computational modeling
and mutagenesis scanning to “lock” E2 NF into desired neutralizing conformations. A rigid E2 NF, together with
modifications to improve protein folding and to minimize the decoy effect of immunodominant epitopes, should
improve the immunogenicity of vaccine antigens and as a result elicit multidonor class bnAbs to the conserved
neutralizing epitopes. (2) To develop E1E2-based vaccine antigens. In addition to E2 NF, the native E1E2
complex also present other conserved bnAb epitopes. We will apply scanning mutagenesis to the interface of
E1 and E2 ectodomains and design novel E1 and E2 fusion constructs to improve the stability and production
of the soluble E1E2 complex for the elicitation of bnAbs targeting the quaternary structure of the complex. (3)
To develop self-assembling antigen-presenting nanoparticle vaccines. The engineered E2 and E1E2
complex will be fused with the scaffold proteins of different nanoparticle platforms to identify a platform optimal
for the multimeric display of HCV antigens to the immune system. Based on our preliminary data, this strategy
will greatly improve the immunogenicity of vaccine antigens and elicit a rapid and potent nAb response. (4) To
evaluate immunogenicity and antibody responses of vaccine candidates in the mouse and non-human
primate (NHP) rhesus macaque models. The engineered E2, E1E2 antigens and nanoparticles will first be
studied in mice to confirm their immunogenicity in vivo and their ability to elicit antibodies that can bind and
neutralize HCV. The antigens and nanoparticles with the best properties in vitro and in mice will be studied
further using the NHP model. We have recently shown that rhesus macaques react to E1E2 immunization in a
manner highly reminiscent to that used by humans and develop bnAbs against E2 NF with genetic similarity to
human bnAbs. Here, we will immunize NHPs, identify bnAbs, and perform repertoire NGS to evaluate selected
antigen designs. The outcome of Project 2 would be a set of well-characterized HCV vaccine candidates.
项目摘要
丙型肝炎病毒(HCV)感染了世界人口的1-2%,对公共卫生构成重大威胁。
最近的研究已经确定了一组广泛中和抗体(bnAb)及其遗传偏好。
与bnAb和非nAb复合的各种HCV E2构建体的晶体结构提供了结构上的互补性。
合理疫苗设计的基础。在本P01建议书的项目2中,我们将结合联合收割机的结构优化,
HCV抗原、纳米颗粒工程、体内评估和B细胞的下一代测序(NGS)
这有助于合理设计可引发bnAb应答的HCV疫苗。具体目标在
本研究的主要目的是:(1)开发针对多供体类抗体反应的疫苗抗原。的
主要的病毒中和位点,E2中和面(E2 NF),是众所周知的多供体类抗体靶标
关于HCV E2 NF在构象上是柔性的,并被免疫显性可变区包围和保护
环和N-聚糖。将通过计算建模优化E2 NF处及其周围的抗原表面
和诱变扫描以将E2 NF“锁定”成所需的中和构象。刚性E2 NF,以及
修饰以改善蛋白质折叠和最小化免疫显性表位的诱饵效应,
提高疫苗抗原的免疫原性,并因此引发针对保守的
中和表位(2)开发基于E1 E2的疫苗抗原。除了E2 NF,天然E1 E2
复合物还呈现其他保守的bnAb表位。我们将扫描诱变应用于
E1和E2胞外域,并设计新的E1和E2融合构建体以提高稳定性和产量
用于引发靶向复合物四级结构的bnAb。(三)
研制自组装抗原提呈纳米颗粒疫苗。E2和E1 E2
复合物将与不同纳米颗粒平台的支架蛋白融合,以确定最佳平台
用于HCV抗原向免疫系统的多聚体展示。根据我们的初步数据,
将大大提高疫苗抗原的免疫原性,并引发快速和有效的nAb应答。(4)到
评价候选疫苗在小鼠和非人中的免疫原性和抗体应答
灵长类(NHP)恒河猴模型。工程化的E2、E1 E2抗原和纳米颗粒将首先被
在小鼠中进行研究,以确认它们的体内免疫原性和它们引发能够结合和
中和HCV。将研究在体外和小鼠中具有最佳性能的抗原和纳米颗粒
进一步使用NHP模型。我们最近发现恒河猴对E1 E2免疫的反应是,
的方式,并开发针对E2 NF的bnAb,其与
人bnAb。在这里,我们将免疫NHP,鉴定bnAb,并进行NGS,以评估选择的
抗原设计项目2的结果将是一组充分表征的HCV候选疫苗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jiang Zhu其他文献
Jiang Zhu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jiang Zhu', 18)}}的其他基金
Novel HCV vaccine antigens and nanoparticles
新型 HCV 疫苗抗原和纳米颗粒
- 批准号:
10428301 - 财政年份:2022
- 资助金额:
$ 56.97万 - 项目类别:
Uncleaved prefusion-optimized trimers on nanoparticles as HIV vaccines
纳米颗粒上未切割的预融合优化三聚体作为 HIV 疫苗
- 批准号:
10307527 - 财政年份:2018
- 资助金额:
$ 56.97万 - 项目类别:
Uncleaved prefusion-optimized trimers on nanoparticles as HIV vaccines
纳米颗粒上未切割的预融合优化三聚体作为 HIV 疫苗
- 批准号:
10062813 - 财政年份:2018
- 资助金额:
$ 56.97万 - 项目类别:
Uncleaved prefusion-optimized trimers on nanoparticles as HIV vaccines
纳米颗粒上未切割的预融合优化三聚体作为 HIV 疫苗
- 批准号:
10524053 - 财政年份:2018
- 资助金额:
$ 56.97万 - 项目类别:
Rational design and B cell responses of HIV epitope vaccines
HIV表位疫苗的合理设计和B细胞反应
- 批准号:
9270983 - 财政年份:2016
- 资助金额:
$ 56.97万 - 项目类别:
Rational design and B cell responses of HIV epitope vaccines
HIV表位疫苗的合理设计和B细胞反应
- 批准号:
10056970 - 财政年份:2016
- 资助金额:
$ 56.97万 - 项目类别:
Novel HCV vaccine antigens targeting conserved neutralizing epitopes
针对保守中和表位的新型 HCV 疫苗抗原
- 批准号:
9096641 - 财政年份:2016
- 资助金额:
$ 56.97万 - 项目类别:
Structure-based immunogen design for hepatitis C virus
基于结构的丙型肝炎病毒免疫原设计
- 批准号:
9091424 - 财政年份:2015
- 资助金额:
$ 56.97万 - 项目类别:
Env-Specific B Cell Repertoire Responses to NFL Trimer vaccines
对 NFL 三聚体疫苗的环境特异性 B 细胞库反应
- 批准号:
9111304 - 财政年份:
- 资助金额:
$ 56.97万 - 项目类别:
Novel HCV vaccine antigens targeting conserved neutralizing epitopes
针对保守中和表位的新型 HCV 疫苗抗原
- 批准号:
9903198 - 财政年份:
- 资助金额:
$ 56.97万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 56.97万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 56.97万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 56.97万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 56.97万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 56.97万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 56.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 56.97万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 56.97万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 56.97万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 56.97万 - 项目类别: